Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invida Goes Deeper In Skincare, Teams With Sinclair To Expand In Asia Pacific

This article was originally published in PharmAsia News

Executive Summary

UK specialty drug maker Sinclair signed a collaborative deal Dec. 7 with Singapore-based Invida to commercialize a number of dermatology products in 11 Asian markets. While multinational drug makers are accelerating expansion in Asia, specialty pharmaceutical companies are teaming up with contract sales firms such as Invida to capitalize on increasing demand in the region

You may also be interested in...



Invida CEO John Graham On Commercializing Products In Asia: An Interview With PharmAsia News (Part 2 of 2)

On the sidelines of the JP Morgan Healthcare Conference, Graham talks about Menarini’s acquisition of Invida, plans for expansion in China and India, and his favorite non-BRIC emerging markets.

Invida CEO John Graham On Commercializing Products In Asia: An Interview With PharmAsia News (Part 1 of 2)

On the sidelines of the JP Morgan Healthcare Conference, Graham talks about Menarini’s acquisition of Invida, plans for expansion in China and India, and his favorite non-BRIC emerging markets.

Asia Beckons: Italy’s Menarini Wins Invida To Maximize Local Identity

Menarini is attracted to Invida for its speedy growth at the back of its Asia presence. Asia-Pacific region represents 10% of the world’s pharmaceutical market with a projected near-term 20% annual growth rate.

Related Content

UsernamePublicRestriction

Register

SC073806

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel